Topic

Blenrep (belantamab mafodotin)

A collection of 29 issues

How to Get Blenrep (belantamab mafodotin) Covered by Cigna in Texas: Forms, Appeals, and Current Access Options

Answer Box: Getting Blenrep (belantamab mafodotin) Covered by Cigna in Texas Current Status: Blenrep is not commercially available in the US (withdrawn 2022; FDA resubmission pending October 2025). For Texas patients with Cigna coverage, access is limited to clinical trials or expanded access programs. If pursuing coverage: Submit Cigna'

How to Get Blenrep (Belantamab Mafodotin) Covered by Blue Cross Blue Shield in Virginia: Current Access Options and Appeals Guide

Answer Box: Blenrep Coverage in Virginia Blenrep (belantamab mafodotin) is not commercially available in the U.S. as of 2025 due to GSK's voluntary withdrawal in 2022 pending FDA resubmission (PDUFA target October 2025). Current access is limited to clinical trials or expanded access programs only. For Blue

Getting Blenrep (Belantamab Mafodotin) Covered by Aetna (CVS Health) in Washington: Complete Access Guide for Current and Future Approval

Answer Box: Current Blenrep Access Through Aetna in Washington Blenrep (belantamab mafodotin) is not commercially available through standard Aetna coverage due to its 2022 FDA withdrawal, with re-approval anticipated October 2025. Current access requires clinical trial enrollment or GSK expanded access programs. Washington residents denied coverage can appeal through Aetna&

How to Get Blenrep (belantamab mafodotin) Covered by Aetna (CVS Health) in Pennsylvania: Appeals Guide with Forms and Timelines

Answer Box: Getting Blenrep Covered in Pennsylvania Blenrep (belantamab mafodotin) received FDA approval on October 23, 2025, for adults with relapsed or refractory multiple myeloma. Aetna (CVS Health) requires prior authorization through CVS Caremark for this specialty drug. If denied, Pennsylvania's external review program overturns approximately 50% of

Get Blenrep (Belantamab Mafodotin) Covered by Blue Cross Blue Shield Michigan: Complete PA and Appeal Guide

Answer Box: Getting Blenrep Coverage in Michigan Blenrep (belantamab mafodotin) is currently withdrawn from the U.S. market but under FDA review for potential resubmission (PDUFA date October 23, 2025). Blue Cross Blue Shield of Michigan requires prior authorization for this specialty oncology drug when available, and current access is

Getting Blenrep (Belantamab Mafodotin) Covered by Humana in North Carolina: PA Requirements, Appeals, and Alternative Options

Answer Box: Fast Track to Blenrep Coverage Blenrep (belantamab mafodotin) received FDA approval on October 23, 2025, for relapsed/refractory multiple myeloma after 2+ prior therapies. Humana Medicare typically covers FDA-approved oncology drugs but requires prior authorization. Your fastest path: 1) Have your oncologist submit Humana's "Request

Getting Blenrep (Belantamab Mafodotin) Covered by UnitedHealthcare in Illinois: PA Requirements, Appeals, and Cost Support

Answer Box: Getting Blenrep Covered by UnitedHealthcare in Illinois Important Update: Blenrep (belantamab mafodotin) was voluntarily withdrawn from the U.S. market in 2022. GSK resubmitted for FDA approval with a PDUFA date of October 23, 2025. Currently, access is limited to clinical trials or expanded access programs only. For

How to Get Blenrep (Belantamab Mafodotin) Approved by UnitedHealthcare in Georgia: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Blenrep Covered by UnitedHealthcare in Georgia Important: Blenrep (belantamab mafodotin) was withdrawn from the US market in November 2022 and remains unavailable for commercial coverage. Access is limited to clinical trials or GSK's expanded access program. UnitedHealthcare will deny coverage requests outside these pathways. If

How to Get Blenrep (Belantamab Mafodotin) Covered by Humana in Texas: PA Requirements, Appeals, and Approval Scripts

Answer Box: Getting Blenrep Covered by Humana in Texas Current Status: Blenrep (belantamab mafodotin) was withdrawn from US markets in 2022 and is only available through clinical trials or expanded access programs. Humana typically denies coverage outside study settings. If pursuing expanded access: (1) Submit prior authorization via Humana'

Getting Blenrep (Belantamab Mafodotin) Covered by Humana in Illinois: Complete Guide to Access, Appeals, and Clinical Trial Options

Answer Box: Getting Blenrep (Belantamab Mafodotin) Covered in Illinois Blenrep is currently unavailable commercially in the U.S. pending FDA re-approval (expected October 2025). Your fastest path to access is through GSK's clinical trials or expanded access program. For Humana coverage once re-approved: submit a coverage determination with